申请人:Otsuka Pharmaceutical Co., Ltd.
公开号:US04788130A1
公开(公告)日:1988-11-29
Novel 2,3-dihydro-1H-indene derivatives and salts thereof represented by the general formula (1), ##STR1## [wherein R.sup.1 and R.sup.2 are each a hydrogen atom, a lower alkyl group, a phenyl group which may have halogen atoms and/or alkyl groups as the substituents on the phenyl ring; R.sup.3 is a halogen atom or a lower alkyl group; R.sup.4 is a hydrogen atom, a halogen atom, a phenyl-lower alkyl group, a cycloalkyl-lower alkyl group or the like; R.sup.5 is a hydroxyimino group, an alkylamino group or a group of the formula --NHR.sup.8 (wherein R.sup.8 is a hydrogen atom, a halogen-substituted lower alkanoyl group or the like); R.sup.6 is a hydrogen atom or a phenyl group; and R.sup.7 is a hydrogen atom or a lower alkyl group]. The 2,3-dihydro-1H-indene derivatives and salt thereof are useful as improving agents for treating anoxemic and hypoxic symptoms and syndromes accompanied therewith, cerebral activators, amnesia curative agents, presbyophrenia curative agents, treating agents for breathing arrest and improving agents for hypoxia accompanied with potassium cyanide poisoning, as well as useful as anti-inflammatory agents and hypotensive agents.
新型2,3-二氢-1H-茚衍生物及其盐由通式(1)表示,其中R.sup.1和R.sup.2分别是氢原子、较低的烷基基团、苯基,苯基上可能有卤原子和/或烷基基团作为取代基;R.sup.3是卤原子或较低的烷基基团;R.sup.4是氢原子、卤原子、苯基-较低烷基基团、环烷基-较低烷基基团或类似物;R.sup.5是羟亚胺基、烷基氨基或式--NHR.sup.8的基团(其中R.sup.8是氢原子、卤代较低脂酰基团或类似物);R.sup.6是氢原子或苯基;R.sup.7是氢原子或较低的烷基基团。这些2,3-二氢-1H-茚衍生物及其盐可用作改善氧缺和缺氧症状及伴随的综合症的治疗剂、脑活化剂、失忆症治疗剂、老年痴呆症治疗剂、呼吸停止治疗剂和改善氰化钾中毒伴随的低氧症的治疗剂,以及作为抗炎剂和降压剂。